Posterior Uveitis - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 66 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Posterior Uveitis - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Posterior Uveitis - Pipeline Review, H2 2015', provides an overview of the Posterior Uveitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Posterior Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Posterior Uveitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Posterior Uveitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Posterior Uveitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Posterior Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Posterior Uveitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Posterior Uveitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Posterior Uveitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Posterior Uveitis Overview 6
Therapeutics Development 7
Pipeline Products for Posterior Uveitis - Overview 7
Posterior Uveitis - Therapeutics under Development by Companies 8
Posterior Uveitis - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Posterior Uveitis - Products under Development by Companies 12
Posterior Uveitis - Companies Involved in Therapeutics Development 13
Aciont Inc. 13
Neuroptis Biotech 14
Oculis ehf 15
pSivida Corp. 16
Regeneron Pharmaceuticals, Inc. 17
ThromboGenics NV 18
Virogenomics, Inc. 19
XOMA Corporation 20
Posterior Uveitis - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
dexamethasone acetate - Drug Profile 30
Mechanism of Action 30
R&D Progress 30
dexamethasone sodium phosphate - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
fluocinolone acetonide SR - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
gevokizumab - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
NOP-3 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Peptides to Modulate TCR for Uveitis - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
sarilumab - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
TG-931 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Posterior Uveitis - Recent Pipeline Updates 46
Posterior Uveitis - Dormant Projects 60
Posterior Uveitis - Product Development Milestones 61
Featured News & Press Releases 61
Sep 28, 2015: pSivida Announces NDA for Medidur Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs 61
May 19, 2015: pSivida Reports Positive IOP Safety Data in Phase III Trial of Medidur for Posterior Uveitis 61
Mar 26, 2015: pSivida Completes Targeted Enrollment of Phase III Trial of Medidur for Posterior Uveitis 62
Apr 15, 2013: Aciont To Present at ARVO 2013 Annual Meeting 63
Oct 03, 2012: Xoma Initiates Phase III Study Of Gevokizumab In Patients With Non-Infectious Uveitis Currently Controlled By Systemic Treatment 63
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 65
Disclaimer 66

List of Tables

Number of Products under Development for Posterior Uveitis, H2 2015 7
Number of Products under Development by Companies, H2 2015 8
Comparative Analysis by Late Stage Development, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 10
Comparative Analysis by Early Stage Development, H2 2015 11
Products under Development by Companies, H2 2015 12
Posterior Uveitis - Pipeline by Aciont Inc., H2 2015 13
Posterior Uveitis - Pipeline by Neuroptis Biotech, H2 2015 14
Posterior Uveitis - Pipeline by Oculis ehf, H2 2015 15
Posterior Uveitis - Pipeline by pSivida Corp., H2 2015 16
Posterior Uveitis - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015 17
Posterior Uveitis - Pipeline by ThromboGenics NV, H2 2015 18
Posterior Uveitis - Pipeline by Virogenomics, Inc., H2 2015 19
Posterior Uveitis - Pipeline by XOMA Corporation, H2 2015 20
Assessment by Monotherapy Products, H2 2015 21
Number of Products by Stage and Target, H2 2015 23
Number of Products by Stage and Mechanism of Action, H2 2015 25
Number of Products by Stage and Route of Administration, H2 2015 27
Number of Products by Stage and Molecule Type, H2 2015 29
Posterior Uveitis Therapeutics - Recent Pipeline Updates, H2 2015 46
Posterior Uveitis - Dormant Projects, H2 2015 60